为解决 nAMD 治疗负担重及双眼给药相关问题，Adverum Biotechnologies 的研究人员开展 ixo-vec 基因疗法研究，发现 6E10 vg/eye 人用剂量有效且双眼交错给药可行，为临床治疗提供依据。 年龄相关性黄斑变性（AMD）如同视力的 “窃贼”，悄然威胁着众多中老年人的视觉 ...

Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant burden associated with ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...